EUVIMEDSkopri EUVIMED
Open access · CC BY-NC-ND 4.0

Who Can Safely Discontinue Treatment in Myasthenia Gravis? Insights From a Long‐Term Real‐World Study

Dingxian He, Chong Yan, Baitong Wang, Yanlei Yang, Shengying Gu, Jianying Xi, Sushan Luo iD, Chongbo Zhao iD

European Journal of Neurology · 2026-03 · 33 (3)

DOI: 10.1111/ene.70569 ↗

At a glance

Journal article in European Journal of Neurology, published online on 2026-03-13. Written by Dingxian He and 7 co-authors. Institution: Huashan Rare Disease Centre and Department of Neurology, Huashan Hospital, Shanghai Medical College, National Centre for Neurological Disorders, Fuda…. Major MEDLINE topics: Myasthenia Gravis, Rituximab, Immunologic Factors. 39 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: National Natural Science Foundation of China, National Clinical Collaboration Project for Major and Difficult Diseases with Integrated Traditional Chinese and Western Medicine.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background

Optimal timing for treatment discontinuation in myasthenia gravis (MG) patients achieving minimal symptom expression (MSE) remains undefined.

Methods

This prospective cohort study enrolled 196 MG patients from the Huashan MG Registry who achieved MSE and subsequently discontinued all treatments. Cox regression was used to identify prognostic factors for relapse. Among these, 20 patients experienced two discontinuation events and were analyzed separately for their second discontinuation.

Results

Over a mean follow‐up of 111.10 months, 108 patients (55.1%) experienced relapse. Multivariate analysis identified four independent prognostic factors: onset age ≥ 50 years as a risk factor (HR 1.68, 95% CI 1.04–2.70, p = 0.032), and rituximab administration (HR 0.43, 95% CI 0.17–0.89, p = 0.015), treatment duration ≥ 14.3 months (HR 0.54, 95% CI 0.34–0.85, p = 0.008), and time from MSE to discontinuation ≥ 6.1 months (HR 0.51, 95% CI 0.32–0.83, p = 0.007) as protective factors. Infection, fatigue, and psychological stress were common relapse triggers.

Conclusions

Complete treatment discontinuation after MSE in MG carries substantial relapse risk. Individualized discontinuation decisions incorporating younger onset age, prior rituximab use, adequate treatment and consolidation duration may optimize outcomes.

Subjects

MeSH terms (MEDLINE)

Myasthenia GravisRituximabImmunologic FactorsHumansFemaleMaleMiddle AgedTreatment InterruptionAdultRegistriesRecurrenceAgedProspective StudiesPrognosisAge of OnsetFollow-Up Studies

Author keywords

minimal symptom expressionmyasthenia gravisprognostic factorsrelapsetreatment discontinuation

Substances

RituximabImmunologic Factors

Authors and institutions

  • Huashan Rare Disease Centre and Department of Neurology, Huashan Hospital, Shanghai Medical College, National Centre for Neurological Disorders, Fudan University, Shanghai, China.
  • Department of Encephalopathy, The Affiliated Hospital to Changchun University of Chinese Medicine, Jilin, Changchun, China.
  • Department of Neurology, Southern Central Hospital of Yunnan Province (The First People's Hospital of Honghe Prefecture), Gejiu, Yunnan, China.

ORCID profiles: Sushan Luo, Chongbo Zhao

Funding

  • National Natural Science Foundation of China
  • National Clinical Collaboration Project for Major and Difficult Diseases with Integrated Traditional Chinese and Western Medicine

Cite

APA

He, D., Yan, C., Wang, B., Yang, Y., Gu, S., Xi, J., Luo, S., & Zhao, C. (2026). Who Can Safely Discontinue Treatment in Myasthenia Gravis? Insights From a Long‐Term Real‐World Study. European Journal of Neurology, 33(3). https://doi.org/10.1111/ene.70569

Vancouver

He D, Yan C, Wang B, Yang Y, Gu S, Xi J, et al. Who Can Safely Discontinue Treatment in Myasthenia Gravis? Insights From a Long‐Term Real‐World Study. European Journal of Neurology. 2026;33(3). doi:10.1111/ene.70569

BibTeX
@article{He2026,
  author = {He, Dingxian and Yan, Chong and Wang, Baitong and Yang, Yanlei and Gu, Shengying and Xi, Jianying and Luo, Sushan and Zhao, Chongbo},
  title = {Who Can Safely Discontinue Treatment in Myasthenia Gravis? Insights From a Long‐Term Real‐World Study},
  journal = {European Journal of Neurology},
  year = {2026},
  volume = {33},
  number = {3},
  doi = {10.1111/ene.70569}
}
Start for free →